#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2280	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2434	271.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1496	1496	C	304	C,A	275,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2280	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2434	271.5	0	HET	.	.	.	A37T	.	37	37	A	349	349	A	332	A,T	236,70	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3804	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4174	273.1	0	.	n	.	0	T695C	SNP	695	695	T	1343	1343	C	288	C,A	247,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3804	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4174	273.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1985	1985	A	313	A	291	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3804	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4174	273.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2619	2619	C	364	C	325	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3804	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4174	273.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3245	3245	T	335	T	297	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3804	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4174	273.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2693	2693	A	374	A	337	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	332	folP	852	852	100.0	folP.l6.c4.ctg.1	1884	52.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1189	1191	AGC	92;92;93	A;G;C	80;81;81	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	814	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3925	62.2	1	SNP	p	S91F	0	.	.	271	273	TCC	824	826	TCC	59;60;60	T;C;C	58;58;57	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	814	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3925	62.2	1	SNP	p	D95G	0	.	.	283	285	GAC	836	838	GAC	60;60;60	G;A;C	57;57;56	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	814	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3925	62.2	1	SNP	p	D95N	0	.	.	283	285	GAC	836	838	GAC	60;60;60	G;A;C	57;57;56	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	314	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1847	50.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	766	768	ACC	89;89;90	A;C;C	76;79;80	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	314	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1847	50.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	781	783	CAC	92;92;92	C;A;C	79;79;82	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	314	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1847	50.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	964	966	CAC	101;101;101	C,A;A;C	89,1;92;92	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	314	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1847	50.8	1	SNP	p	G45D	0	.	.	133	135	GGC	784	786	GGC	92;92;93	G;G;C	78;78;82	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	244	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1390	52.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	888	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3741	71.3	1	SNP	p	D86N	0	.	.	256	258	GAC	1100	1102	GAC	88;87;87	G;A;C	81;75;79	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	888	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3741	71.3	1	SNP	p	S87I	0	.	.	259	261	AGT	1103	1105	AGT	87;88;88	A;G;T	74;82;77	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	888	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3741	71.3	1	SNP	p	S87R	0	.	.	259	261	AGT	1103	1105	AGT	87;88;88	A;G;T	74;82;77	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	888	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3741	71.3	1	SNP	p	S87W	0	.	.	259	261	AGT	1103	1105	AGT	87;88;88	A;G;T	74;82;77	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	888	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3741	71.3	1	SNP	p	S88P	0	.	.	262	264	TCC	1106	1108	TCC	88;88;88	T;C;C	82;79;80	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	666	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3096	64.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1773	1775	GGC	78;79;78	G;G;C	70;69;69	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1444	1446	GCA	97;97;97	G;C;A	87;89;88	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1447	1449	ATC	97;97;99	A,C;T;C	85,1;85;90	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1459	1461	GTG	100;100;100	G;T;G	86;88;82	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1459	1461	GTG	100;100;100	G;T;G	86;88;82	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1963	1965	ACC	74;74;75	A;C;C	65;71;71	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2017	2019	GCG	74;74;73	G;C;G	70;57;62	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2017	2019	GCG	74;74;73	G;C;G	70;57;62	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2140	2142	GGC	77;77;76	G;G;C	66;67;63	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2149	2151	GGC	76;77;76	G;G;C	67;68;65	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	65.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2167	2169	CCG	76;75;75	C;C;G	66;62;62	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	834	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3500	71.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1778	1780	CTG	81;81;83	C;T;G	73;70;71	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	390	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2440	48.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	874	874	C	61	C	53	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	60	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1442	11.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1296	1298	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	60	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1442	11.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1299	1301	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	60	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1442	11.9	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1311	1313	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	60	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1442	11.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1323	1325	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	60	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1442	11.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1346	1348	GTA	1;1;1	G;T;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	60	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1442	11.9	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1358	1358	G	1	G	1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	0	.	p	.	0	G50N	NONSYN	148	150	GGC	729	731	AAC	106;105;105	A,G;A;C	95,1;93;94	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	984	986	CTT	100;100;100	C;T;T,G	90;91;91,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1008	1010	GGA	102;102;104	G;G;A	92;88;92	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1092	1094	GGT	108;108;108	G,A;G,A;T,C	97,1;97,1;99,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1146	1148	AGC	107;107;108	A;G,A;C	98;102,1;102	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1212	1212	T	96	T	87	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	1	SNP	p	G120K	0	.	.	358	360	GGT	939	941	GGT	106;105;106	G;G,A;T,G	91;90,1;90,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	1	SNP	p	A121N	0	.	.	361	363	GCC	942	944	GCC	107;107;107	G,T;C,A;C	89,1;94,1;95	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	470	porB1b	1035	1035	95.73	porB1b.l15.c4.ctg.1	1997	69.7	1	SNP	p	A121D	0	.	.	361	363	GCC	942	944	GCC	107;107;107	G,T;C,A;C	89,1;94,1;95	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1420	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5721	74.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2278	2280	AAT	94;93;92	A;A;T	82;81;80	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	214	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1501	42.6	1	SNP	p	V57M	1	.	.	169	171	ATG	818	820	ATG	69;69;70	A;T;G	65;66;67	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
